BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramos-Sevillano E, Rodríguez-Sosa C, Cafini F, Giménez MJ, Navarro A, Sevillano D, Alou L, García E, Aguilar L, Yuste J. Cefditoren and ceftriaxone enhance complement-mediated immunity in the presence of specific antibodies against antibiotic-resistant pneumococcal strains. PLoS One 2012;7:e44135. [PMID: 22957048 DOI: 10.1371/journal.pone.0044135] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Miyazaki T, Fukushima K, Hashiguchi K, Inoue Y, Mihara T, Sawai T, Suyama N, Kobayashi T, Kondo A, Fukuda Y, Harada Y, Sasaki E, Kaku N, Ide S, Takazono T, Saijo T, Kosai K, Morinaga Y, Nakamura S, Yamamoto K, Imamura Y, Izumikawa K, Yanagihara K, Kohno S, Mukae H. Efficacy and safety of cefditoren pivoxil for exacerbations of chronic obstructive pulmonary disease: A prospective multicenter interventional study. J Infect Chemother 2019;25:702-7. [PMID: 30982729 DOI: 10.1016/j.jiac.2019.03.018] [Reference Citation Analysis]
2 Murphy TK, Parker-Athill EC, Lewin AB, Storch EA, Mutch PJ. Cefdinir for recent-onset pediatric neuropsychiatric disorders: a pilot randomized trial. J Child Adolesc Psychopharmacol 2015;25:57-64. [PMID: 25299463 DOI: 10.1089/cap.2014.0010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
3 Sempere J, González-Camacho F, Domenech M, Llamosí M, Del Río I, López-Ruiz B, Gimeno M, Coronel P, Yuste J. A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004-20 in Spain. J Antimicrob Chemother 2022:dkab482. [PMID: 35045160 DOI: 10.1093/jac/dkab482] [Reference Citation Analysis]
4 Ngwa DN, Singh SK, Agrawal A. C-Reactive Protein-Based Strategy to Reduce Antibiotic Dosing for the Treatment of Pneumococcal Infection. Front Immunol 2020;11:620784. [PMID: 33552084 DOI: 10.3389/fimmu.2020.620784] [Reference Citation Analysis]
5 Vázquez R, García P. Synergy Between Two Chimeric Lysins to Kill Streptococcus pneumoniae. Front Microbiol 2019;10:1251. [PMID: 31231338 DOI: 10.3389/fmicb.2019.01251] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
6 Domenech M, Sempere J, de Miguel S, Yuste J. Combination of Antibodies and Antibiotics as a Promising Strategy Against Multidrug-Resistant Pathogens of the Respiratory Tract. Front Immunol 2018;9:2700. [PMID: 30515172 DOI: 10.3389/fimmu.2018.02700] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
7 Giménez MJ, Aguilar L, Granizo JJ. Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults. Multidiscip Respir Med 2018;13:40. [PMID: 30410757 DOI: 10.1186/s40248-018-0152-5] [Reference Citation Analysis]
8 Díez-Martínez R, de Paz HD, Bustamante N, García E, Menéndez M, García P. Improving the lethal effect of cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module. Antimicrob Agents Chemother 2013;57:5355-65. [PMID: 23959317 DOI: 10.1128/AAC.01372-13] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
9 Richi P, Yuste J, Navío T, González-Hombrado L, Salido M, Thuissard-Vasallo I, Jiménez-Díaz A, Llorente J, Cebrián L, Lojo L, Steiner M, Cobo T, Martín MD, García-Castro M, Castro P, Muñoz-Fernández S. Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases. Vaccines (Basel) 2021;9:203. [PMID: 33671007 DOI: 10.3390/vaccines9030203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Huang W, Zhang Q, Li W, Chen Y, Shu C, Li Q, Zhou J, Ye C, Bai H, Sun W, Yang X, Ma Y. Anti-outer Membrane Vesicle Antibodies Increase Antibiotic Sensitivity of Pan-Drug-Resistant Acinetobacter baumannii. Front Microbiol 2019;10:1379. [PMID: 31275290 DOI: 10.3389/fmicb.2019.01379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
11 Ngwa DN, Agrawal A. Structure-Function Relationships of C-Reactive Protein in Bacterial Infection. Front Immunol 2019;10:166. [PMID: 30863393 DOI: 10.3389/fimmu.2019.00166] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
12 Barrera-Vargas A, Gómez-Martín D, Merayo-Chalico J, Ponce-de-León A, Alcocer-Varela J. Risk factors for drug-resistant bloodstream infections in patients with systemic lupus erythematosus. J Rheumatol 2014;41:1311-6. [PMID: 24882843 DOI: 10.3899/jrheum.131261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
13 Corsini B, Aguinagalde L, Ruiz S, Domenech M, Yuste J. Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System. Vaccines (Basel) 2021;9:186. [PMID: 33672306 DOI: 10.3390/vaccines9020186] [Reference Citation Analysis]
14 Corsini B, Aguinagalde L, Ruiz S, Domenech M, Antequera ML, Fenoll A, García P, García E, Yuste J. Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis. Vaccine 2016;34:6148-57. [PMID: 27840016 DOI: 10.1016/j.vaccine.2016.11.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
15 Szczepanek SM, Roberts S, Rogers K, Cotte C, Adami AJ, Bracken SJ, Salmon S, Secor ER Jr, Thrall RS, Andemariam B, Metzger DW. Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers. PLoS One 2016;11:e0149261. [PMID: 26910228 DOI: 10.1371/journal.pone.0149261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]